These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21102646)

  • 41. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
    Fialoke S; Malarstig A; Miller MR; Dumitriu A
    AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Prashanth M; Ganesh HK; Vima MV; John M; Bandgar T; Joshi SR; Shah SR; Rathi PM; Joshi AS; Thakkar H; Menon PS; Shah NS
    J Assoc Physicians India; 2009 Mar; 57():205-10. PubMed ID: 19588648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese.
    Strey CBM; de Carli LA; Fantinelli M; Gobbato SS; Bassols GF; Losekann A; Coral GP
    Ann Hepatol; 2018 July - August ,; 17(4):585-591. PubMed ID: 29893699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alcoholic and nonalcoholic forms of fatty liver disease.
    Forgione A; Miele L; Cefalo C; Gasbarrini G; Grieco A
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):83-100. PubMed ID: 17415346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan.
    Hsu CS; Kao JH
    J Formos Med Assoc; 2012 Oct; 111(10):527-35. PubMed ID: 23089687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetes and nonalcoholic fatty liver disease.
    Kantartzis K; Gastaldelli A; Magkos F; Lavoie JM
    Exp Diabetes Res; 2012; 2012():404632. PubMed ID: 22194736
    [No Abstract]   [Full Text] [Related]  

  • 48. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.
    Lee YH; Cho Y; Lee BW; Park CY; Lee DH; Cha BS; Rhee EJ
    Diabetes Metab J; 2019 Feb; 43(1):31-45. PubMed ID: 30793550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diagnostic significance of serum -glucuronidase. IV. Serum -glucuronidase activity in arteriosclerosis and diabetes mellitus].
    Nilius R; Krosch H; Zipprich KW
    Z Gesamte Inn Med; 1971 Jun; 26(12):393-7. PubMed ID: 4256412
    [No Abstract]   [Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease.
    Paredes AH; Torres DM; Harrison SA
    Clin Liver Dis; 2012 May; 16(2):397-419. PubMed ID: 22541706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Non-alcoholic fatty liver: the hepatologic stakes and the metabolic stakes].
    Traverso M
    Ann Endocrinol (Paris); 2003 Dec; 64(6):478-80. PubMed ID: 15080158
    [No Abstract]   [Full Text] [Related]  

  • 52. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease?
    Sargin M; Uygur-Bayramiçli O; Sargin H; Orbay E; Yayla A
    J Clin Gastroenterol; 2003; 37(5):399-402. PubMed ID: 14564188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
    Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
    Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Liver disease spectrum in hospitalized type 2 diabetes and related risk factors analysis of non-alcoholic fatty liver disease].
    Yan Y; Bian H; Xia MF; Yan HM; Chang XX; Yao XZ; Rao SX; Zeng MS; Gao X
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(4):270-4. PubMed ID: 23578506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonalcoholic fatty liver disease in India - a lot done, yet more required!
    Duseja A
    Indian J Gastroenterol; 2010 Nov; 29(6):217-25. PubMed ID: 21191681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.
    Targher G; Lonardo A; Byrne CD
    Nat Rev Endocrinol; 2018 Feb; 14(2):99-114. PubMed ID: 29286050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Non-alcoholic steatohepatitis--a new epidemic].
    Maier KP
    Praxis (Bern 1994); 2007 Nov; 96(47):1857-60. PubMed ID: 18062158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus.
    Takemoto M; Yamaga M; Furuichi Y; Yokote K
    J Am Geriatr Soc; 2015 Jun; 63(6):1271-3. PubMed ID: 26096415
    [No Abstract]   [Full Text] [Related]  

  • 60. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.